Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against OvaScience, Inc. (“OvaScience” or the “Company”) (Nasdaq: OVAS) concerning possible violations of federal securities laws between January 8, 2015 and March 26, 2015 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm by the May 26, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, during the Class Period, OvaScience issued false and misleading statements and/or failed to disclose that: the science behind AUGMENT, a treatment specifically designed to improve a patient’s egg health, had not been scientifically validated; that the Company was unable to achieve the purported success rates it claimed; and that at all relevant times, the Company’s profitability and prospects were false and misleading. When this news was disclosed to the public, shares of OvaScience dropped in value, harming investors.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.